Franklin Templeton raises stake in Metropolis Healthcare to 5.1%

scanx
Reviewed by
Riya DScanX News Team
Key Highlights
  • Franklin Templeton Mutual Fund acquired 7,42,409 shares of Metropolis Healthcare
  • Total stake rose from 4.742% to 5.1% following the open market purchase
  • Acquisition executed entirely via Franklin India Opportunities Fund
  • Other Franklin Templeton schemes maintained unchanged holdings
  • Transaction disclosed under SEBI SAST Regulations on September 7, 2026
powered bylight_fuzz_icon
50322900

*this image is generated using AI for illustrative purposes only.

Franklin Templeton Mutual Fund increased its stake in Metropolis Healthcare to 5.1% following an open market acquisition of 7,42,409 shares on September 4, 2026. This purchase represents a 0.358% addition to the company’s total voting capital.

The acquisition brings the mutual fund’s total holding to 10,577,754 shares. Prior to this transaction, Franklin Templeton held 98,35,345 shares, accounting for 4.742% of the equity share capital. The company’s total equity share capital remains unchanged at 207,387,568 shares.

Scheme-Wise Breakdown

The entire acquisition was executed through the Franklin India Opportunities Fund. Other schemes within the Franklin Templeton umbrella maintained their existing holdings during this period.

Scheme Name Pre-Acquisition Holding Shares Acquired Post-Acquisition Holding % of Total Shares
Franklin India Opportunities Fund 32,99,036 7,42,409 40,41,445 1.949%
Franklin India Small Cap Fund 47,74,465 0 47,74,465 2.302%
Franklin India Balanced Advantage Fund 5,52,956 0 5,52,956 0.267%
Franklin India Aggressive Hybrid Fund 5,12,956 0 5,12,956 0.247%
Franklin India Flexi Cap Fund 4,57,741 0 4,57,741 0.221%
Franklin India Multi Asset Allocation Fund 1,64,717 0 1,64,717 0.079%
Franklin India Retirement Fund 58,826 0 58,826 0.028%
Franklin India Conservative Hybrid Fund 14,648 0 14,648 0.007%
Total 98,35,345 7,42,409 1,05,77,754 5.100%

What the Numbers Show

The acquisition activity was concentrated entirely within the Franklin India Opportunities Fund, which increased its stake from 1.591% to 1.949%. In contrast, the largest single scheme holder, the Franklin India Small Cap Fund, did not alter its position, maintaining a static holding of 47,74,465 shares (2.302%). This indicates a targeted rebalancing by the Opportunities Fund rather than a broad-based increase across all Franklin Templeton schemes.

The disclosure was filed under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The shares acquired are equity shares carrying voting rights, with no encumbrances or convertible securities involved in the transaction.

Historical Stock Returns for Metropolis Healthcare

1 Day5 Days1 Month6 Months1 Year5 Years
-1.86%-1.82%-1.15%+25.17%+3.32%0.0%

What specific catalysts or financial metrics prompted the Franklin India Opportunities Fund to selectively increase its stake in Metropolis Healthcare while other schemes remained static?

How might this concentrated accumulation by a major mutual fund influence Metropolis Healthcare's stock volatility and institutional investor sentiment in the near term?

Does this targeted rebalancing signal a broader shift in Franklin Templeton's strategy towards the healthcare diagnostics sector amidst current market conditions?

like20
dislike

Metropolis Healthcare Latest Results: targets ₹2,500 crore organic revenue in three-year plan

scanx
Reviewed by
Shriram SScanX News Team
Key Highlights
  • Metropolis Healthcare has set a target of ₹2,500 crore in annual organic revenue
  • The target is part of a three-year strategic plan
  • The growth strategy is focused on organic expansion within the diagnostics business
powered bylight_fuzz_icon
49952072

*this image is generated using AI for illustrative purposes only.

Metropolis Healthcare has set a target of ₹2,500 crore in annual organic revenue under a three-year strategic plan, according to reports.

Strategic revenue target

The diagnostics company has outlined plans to achieve ₹2,500 crore in annual organic revenue over the course of its three-year roadmap. The target reflects the company's focus on organic growth within its core diagnostics business.

Parameter Details
Revenue target ₹2,500 crore
Plan horizon Three years
Growth type Organic

Growth focus

The three-year plan centres on organic revenue generation, distinguishing it from inorganic or acquisition-led expansion strategies. Metropolis Healthcare's target of ₹2,500 crore underscores the company's intent to scale its operations through internal business development over the defined period.

Historical Stock Returns for Metropolis Healthcare

1 Day5 Days1 Month6 Months1 Year5 Years
-1.86%-1.82%-1.15%+25.17%+3.32%0.0%

What specific operational initiatives or technological investments will Metropolis Healthcare prioritize to achieve this ₹2,500 crore organic revenue target?

How does this aggressive organic growth plan position Metropolis against competitors who are pursuing acquisition-led expansion strategies in the diagnostics sector?

What are the projected impacts on Metropolis Healthcare's profit margins and EBITDA as it scales its core operations over the next three years?

like20
dislike

More News on Metropolis Healthcare

1 Year Returns:+3.32%